CG Oncology, Inc. Common stock
CG Oncology, Inc. Common stock (CGON) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · CGON · as of Sep 30, 2025
Ownership Breakdown
183
Institutional Holders
▲ 14 vs Q2
$3.13B
Total Inst. Value
▲ $1.15B vs Q2
88.20M
Shares Outstanding
freeFloat 74.63%
77.65M
13F Shares Held
▲ 1.73M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
CGON largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
VANGUARD GROUP INC biological products, (no diagnostic substances) | 6.58M | 8.63% | 8.63% | $264.93B | Nov 7, 2025 | ▲ 670.8K |
DECHENG CAPITAL LLC biological products, (no diagnostic substances) | 6.37M | 8.36% | 8.36% | $256.65B | Nov 14, 2025 | — held |
WELLINGTON MANAGEMENT GROUP LLP biological products, (no diagnostic substances) | 5.51M | 7.23% | 7.23% | $222.05B | Nov 14, 2025 | ▲ 3.61M |
BLACKROCK, INC. biological products, (no diagnostic substances) | 4.59M | 6.02% | 6.02% | $184.74B | Nov 12, 2025 | ▲ 130.1K |
FMR LLC biological products, (no diagnostic substances) | 3.87M | 5.07% | 5.07% | $155.71B | Nov 13, 2025 | ▲ 9.5K |
TCG CROSSOVER MANAGEMENT, LLC biological products, (no diagnostic substances) | 3.67M | 4.81% | 4.81% | $147.84B | Nov 17, 2025 | — held |
BRAIDWELL LP biological products, (no diagnostic substances) | 3.28M | 4.31% | 4.31% | $132.25B | Nov 14, 2025 | — held |
FORESITE CAPITAL MANAGEMENT VI LLC biological products, (no diagnostic substances) | 2.22M | 2.91% | 2.91% | $89.48B | Nov 14, 2025 | — held |
ALLIANCEBERNSTEIN L.P. biological products, (no diagnostic substances) | 2.14M | 2.80% | 2.80% | $86.12B | Nov 14, 2025 | ▼ 26.1K |
UBS GROUP AG biological products, (no diagnostic substances) | 2.13M | 2.79% | 2.79% | $85.65B | Nov 13, 2025 | ▼ 103.0K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
21
Increased
+6.52M shares1
New Positions
first time holders18
Decreased
−4.71M shares0
Sold Out
fully exitedNet shares change (top 50)
+1.81M
+6.52M / −4.71M
Net new holders
+4
1 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
CGON insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
13
Buy transactions
4
Sell transactions
3.25
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Liu Brian Guan-Chyun director | Jun 4, 2026 | Award | 9,354 | $56.09 | $524.7K | 9.4K | Form 4 ↗ |
Tong Victor Edward Jr director | Jun 4, 2026 | Award | 9,354 | $56.09 | $524.7K | 9.4K | Form 4 ↗ |
Mulay James director | Jun 4, 2026 | Award | 9,354 | $56.09 | $524.7K | 9.4K | Form 4 ↗ |
POST LEONARD E director | Jun 4, 2026 | Award | 9,354 | $56.09 | $524.7K | 9.4K | Form 4 ↗ |
Rossi Christina director | Jun 4, 2026 | Award | 9,354 | $56.09 | $524.7K | 9.4K | Form 4 ↗ |
POST LEONARD E director | Jun 4, 2026 | Sale | 1,000 | $54.50 | $54.5K | 0 | Form 4 ↗ |
Graf Susan E director | Jun 4, 2026 | Award | 9,354 | $56.09 | $524.7K | 9.4K | Form 4 ↗ |
Mulay James director | Apr 17, 2026 | Sale | 15,600 | $73.01 | $1.14M | 0 | Form 4 ↗ |
Bellete Ambaw President and COO | Apr 15, 2026 | Award | 107,508 | $67.68 | $7.28M | 107.5K | Form 4 ↗ |
Kasturi Vijay Chief Medical Officer | Apr 15, 2026 | Award | 79,216 | $67.68 | $5.36M | 79.2K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
CG Oncology, Inc. Common stock (CGON) is primarily owned by institutional investors, who hold approximately 88.0% of total shares outstanding. Company insiders own approximately 25.37%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of CG Oncology, Inc. Common stock is VANGUARD GROUP INC, holding approximately 6.58 million shares — equal to 8.63% of outstanding shares — as of September 30, 2025.
A total of 183 institutional investors currently hold CGON stock, with a combined institutional value of approximately $3.13 billion as of the most recent 13F filing period.
Frequently asked questions
CGON ownershipCG Oncology, Inc. Common stock (CGON) is primarily owned by institutional investors, who hold approximately 88.0% of shares. The largest shareholder is VANGUARD GROUP INC with a 8.63% stake. Company insiders hold 25.37%. Data sourced from SEC Form 13F as of September 30, 2025.